Panthera Biopartners (Panthera), the LDC-backed UK based clinical trial Site Management Organisation (SMO), has announced the acquisition of Óbudai Egészségügyi Centrum Kft (OEC), a Hungary-based independent clinical research site network. The deal marks the major first step in Panthera’s European expansion strategy.
The acquisition follows Panthera’s investment from LDC (alongside reinvestment from BGF) in August 2025. The investment was made to support Panthera’s ambition to become a major clinical research player across Europe through targeted international expansion.
“This acquisition represents a major milestone for Panthera as we expand into mainland Europe,” said Stuart Young, CEO of Panthera. “OEC is a well-established organisation in Hungary with an outstanding reputation for quality, efficiency and patient access. By bringing together leading businesses in the UK and Hungary, we are creating a powerful platform to deliver faster, more reliable clinical trials at scale.”
Established in 1997, OEC is a leading independent CRO and the only non-academic site network operating at scale in the country. It has built a high-quality, commercially successful clinical trials business, delivering Phase II–IV studies across a broad range of therapeutic areas.
The transaction adds four Hungarian sites to Panthera’s network: Budapest, Zalaegerszeg, Dunaújváros and Kaposvár. Together with over 70 specialist investigators, these sites provide access to diverse patient populations and strong regional recruitment capabilities.
Hungary is an increasingly attractive market for clinical research, thanks to its highly regarded investigators, engaged patient populations and competitive cost base, according to Panthera. The combined network will provide sponsors with enhanced access to patients across the UK and EU and enhances the position of the Panthera-OEC group within the global clinical trials landscape.
“Joining Panthera enables us to scale our capabilities, expand our reach, and continue delivering high-quality clinical trials for sponsors and CRO partners across Europe,” said Gábor Kiss, managing director of OEC.